Canada declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Insurance
Page 2 of 10 of this archive, newest first.
Mexico caps dulaglutide prescribing to 4 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Japan declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Ireland declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Denmark caps tirzepatide prescribing to 13 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Singapore declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Argentina declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Brazil caps exenatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Portugal caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Singapore declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
South Korea caps tirzepatide prescribing to 24 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Saudi Arabia declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Australia caps exenatide prescribing to 21 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Australia declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Canada caps exenatide prescribing to 9 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The United Arab Emirates declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
New Zealand declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Canada declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Saudi Arabia caps tirzepatide prescribing to 13 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
South Korea caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.